Munich Leukemia Laboratory: Utilizing NGS for new insights into leukemia and lymphoma

October 28, 2017

Dr Torsten Haferlach of Munich Leukemia Laboratory (MLL) discusses their goal to sequence, by whole genome sequencing, 5,000 patients with different kinds of leukemias and lymphomas—ultimately understanding the baseline of the disease. Hear how they’re utilizing the flow cells and scalability of the NovaSeq™ 6000 System to expand their research further than before.

View related videos

View related webinars

View related information

Subscribe to the Illumina video channel

For Research Use Only. Not for use in diagnostic procedures.

Share this article on    
    
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see www.illumina.com/company/legal.html.

© 2022 Illumina, Inc. All rights reserved.